• 3973 Citations
  • 31 h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

The general research area of Dr. Mathew’s laboratory is Cancer Immunology. His research focuses on the Cellular and Molecular Biology of human natural killer (NK) cells and their recognition by cancer cells. NK cells are a subpopulation of lymphocytes that play an important role against cancer and various viral and bacterial infections.
Dr. Mathew is one of the pioneers who identified, cloned, and characterized several receptors expressed on human NK cells including 2B4 (CD244, SLAMF4), CS1 (CD319, SLAMF7) and LLT1 (CLEC-­2D). Research in his laboratory has identified their ligands, elucidated the signaling pathways, and also determined the transcriptional regulation of these genes in health and disease conditions. Dr. Mathew has shown that anti-­CS1 antibody activates NK cell cytotoxicity against various cancer cells. The FDA has approved a humanized anti-­CS1 mAb, Empliciti, as a breakthrough drug for multiple myeloma treatment. Thus, his research has led to the development of novel NK cell based immunotherapy for cancer. Current focus is identification of markers for cancer stem cells (CSCs) and targeting CSCs to NK cell mediated killing.

Education/Academic qualification

BS in Physics, University of Kerala

MS in Biochemistry, University of Poona

PhD in Biochemistry, University of Poona

Fingerprint Dive into the research topics where Porunelloor Mathew is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

  • 3973 Citations
  • 31 h-Index
  • 57 Article
  • 6 Review article
  • 1 Chapter
  • 1 Short survey

Roles of nk cell receptors 2b4 (Cd244), cs1 (cd319), and llt1 (clec2d) in cancer

Buller, C. W., Mathew, P. A. & Mathew, S. O., Jul 2020, In : Cancers. 12, 7, p. 1-15 15 p., 1755.

Research output: Contribution to journalReview article

Open Access
  • 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer

    Malaer, J. D., Marrufo, A. M. & Mathew, P. A., Jul 2019, In : Clinical Immunology. 204, p. 50-56 7 p.

    Research output: Contribution to journalReview article

  • 3 Scopus citations

    A novel ligand on astrocytes interacts with natural cytotoxicity receptor NKp44 regulating immune response mediated by NK cells

    Bowen, K. E., Mathew, S. O., Borgmann, K., Ghorpade, A. & Mathew, P. A., Feb 2018, In : PLoS ONE. 13, 2, e0193008.

    Research output: Contribution to journalArticle

  • 4 Scopus citations

    CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

    Malaer, J. D. & Mathew, P., 1 Jan 2017, In : American Journal of Cancer Research. 7, 8, p. 1637-1641 5 p.

    Research output: Contribution to journalReview article

  • 17 Scopus citations

    Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells

    Kim, J. R., Mathew, S. O. & Mathew, P., 1 Jan 2016, In : Immunobiology. 221, 1, p. 31-39 9 p.

    Research output: Contribution to journalArticle

  • 10 Scopus citations